Clonazepam is a prescription medication commonly used to treat anxiety and seizure disorders. However, in recent years, there has been a surge in the online market for Clonazepam as a “research chemical,” a term often used as a thinly veiled guise for selling potentially dangerous substances. This trend has raised serious concerns about the legitimacy and safety of Clonazepam sold by online sellers and vendors.
One of the primary issues with Clonazepam being available for sale online as a research chemical is the lack of regulation and oversight. Unlike legitimate pharmaceutical products, these online sellers often operate in a gray area, bypassing the rigorous quality control standards required for pharmaceuticals. This poses significant risks to consumers who may unwittingly purchase a counterfeit or impure product, jeopardizing their health.
Furthermore, the marketing of Clonazepam as a “designer drug” or “research chemical” is misleading and ethically questionable. These terms are typically associated with novel psychoactive substances, many of which have unknown safety profiles and are associated with various adverse health effects. Clonazepam, on the other hand, is a well-studied and FDA-approved medication with a clear medical purpose. Presenting it as a research chemical undermines the credibility of legitimate scientific research and raises concerns about the intentions of these sellers.
Individuals need to exercise extreme caution when considering purchasing Clonazepam or any other substance online, especially from sources that use ambiguous terminology to market their products. The potential risks to health and safety are too significant to ignore. Instead, individuals seeking Clonazepam or similar medications should consult a healthcare professional and obtain a prescription through legal channels to ensure their well-being is not compromised by unregulated online vendors. In conclusion, the sale of Clonazepam as a research chemical online is a concerning trend that warrants scrutiny and regulatory intervention to protect the public from potential harm.
- 1 Summary
- 2 Chemistry
- 3 Pharmacology
- 4 Subjective effects
- 5 Toxicity
- 6 Legal status
- 7 FAQ
- 7.1 1. What is Clonazepam?
- 7.2 2. How does Clonazepam work?
- 7.3 3. What are the common uses of Clonazepam?
- 7.4 4. How should I take Clonazepam?
- 7.5 5. What are the potential side effects of Clonazepam?
- 7.6 6. Is Clonazepam addictive?
- 7.7 7. Can I drink alcohol while taking Clonazepam?
- 7.8 8. How long does it take for Clonazepam to work?
- 7.9 9. Can I stop taking Clonazepam suddenly?
- 7.10 10. Is Clonazepam safe during pregnancy and breastfeeding?
- 7.11 11. Can Clonazepam interact with other medications?
- 7.12 12. How should I store Clonazepam?
- 7.13 13. Is Clonazepam available over-the-counter (OTC)?
- 7.14 14. Can I drive or operate heavy machinery while taking Clonazepam?
- 7.15 15. What should I do if I miss a dose of Clonazepam?
- 8 References
Clonazepam, known by its trade names Klonopin or Rivotril, belongs to the benzodiazepine class of psychoactive substances. This compound primarily exerts anxiolytic effects, effectively reducing anxiety while displaying anticonvulsant, muscle relaxant, amnesic, sedative, depressant, and hypnotic properties. The medication holds FDA approval for treating panic disorder, generalized anxiety disorder (GAD), and social anxiety disorder (SAD). In Europe, it is generally sanctioned for managing treatment-resistant epilepsy.
Clonazepam is characterized by its lengthy elimination half-life, which spans approximately 30 to 40 hours, categorizing it as a long-acting benzodiazepine. This extended half-life is advantageous for individuals requiring consistent symptom relief. Notably, Clonazepam exhibits a rapid onset of action, with peak blood levels typically reached within one to four hours following oral administration.
It is essential to recognize that abruptly discontinuing benzodiazepines can pose a severe risk to individuals using them regularly over extended periods. Sudden withdrawal can be potentially life-threatening. Therefore, a gradual tapering approach is highly recommended, wherein the dosage is incrementally reduced over an extended duration. Failing to follow this tapering regimen can lead to significant health complications and, in extreme cases, fatal outcomes. It underscores the critical importance of seeking medical guidance and supervision when discontinuing Clonazepam or any benzodiazepine medication to ensure the safety and well-being of individuals who have relied on these substances for therapeutic purposes.
|CompTox Dashboard (EPA)||DTXSID1022845|
|Chemical and physical data|
|Molar mass||315.71 g·mol−1|
Clonazepam is a member of the benzodiazepine drug class. Benzodiazepines are characterized by a molecular structure comprising a benzene ring fused with a diazepine ring, the latter being a seven-membered ring featuring nitrogen atoms at positions R1 and R4. In the case of clonazepam, the benzyl ring is substituted at position R8 with a nitro group, denoted as NO2-. Furthermore, the diazepine ring is connected at position R5 to a phenyl ring bearing a chlorine atom at position 2. Notably, clonazepam also possesses an oxygen group that forms a double bond with position R2 of its diazepine ring, resulting in a ketone. This particular oxygen substitution at R2 is a characteristic feature shared by other benzodiazepine drugs bearing the suffix -diazepam in their names.
Benzodiazepines exert a range of effects through their interaction with the benzodiazepine receptor site, enhancing the efficiency and impact of the neurotransmitter gamma-aminobutyric acid (GABA) by engaging with its receptors. Given that this receptor site is the predominant set of inhibitory receptors in the brain, the modulation of GABA activity leads to the calming and sedating effects of clonazepam on the nervous system.
It is worth noting that the anticonvulsant properties of benzodiazepines might be attributed, at least in part, to their binding to voltage-dependent sodium channels rather than their interaction with benzodiazepine receptors.lowering insulin synthesis
Disclaimer: The effects mentioned below are derived from the Subjective Effect Index (SEI), a compilation of anecdotal user experiences and analyses by contributors to PsychonautWiki. Consequently, these effects should be approached with a healthy dose of skepticism.
Recognizing that these effects may not manifest predictably or consistently is crucial. Higher doses are more likely to encompass the full range of effects but also elevate the risk of adverse outcomes, including addiction, severe harm, or even fatality ☠.
- Sedation: This substance has the potential to induce profound sedation, often resulting in an overwhelming sense of lethargy. At higher doses, individuals may feel intensely sleep-deprived, pushing them to constantly teeter on the brink of passing out rather than engaging in physical activities.
- Muscle Relaxation: This effect is notably potent when compared to alprazolam.
- Loss of Motor Control
- Respiratory Depression
- Seizure Suppression
- Physical Euphoria: Clonazepam shares similarities with alprazolam in providing moderate to solid feelings of bodily relaxation, pleasure, and comfort despite emotional suppression. This effect is more commonly reported by those with pre-existing anxiety but is inconsistent for all users.
- Visual Acuity Suppression: Like many depressants, clonazepam is known to cause blurred or diminished visual acuity.
- Paradoxical Reactions: Benzodiazepines may occasionally lead to paradoxical reactions, such as increased seizures (in people with epilepsy), heightened aggression, elevated anxiety, violent behavior, loss of impulse control, irritability, and suicidal tendencies. These reactions are rare in the general population, with an incidence rate below 1%, but occur more frequently in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimens.
- Anxiety Suppression
- Thought Deceleration
- Suppression of Analysis
- Delusions of Sobriety: A false belief that one is perfectly sober despite clear evidence to the contrary, such as severe cognitive impairment and difficulty communicating. This is more common at high dosages.
- Compulsive Redosing
- Emotion Suppression: While primarily reducing anxiety, clonazepam also dampens other emotions, though to a lesser extent than antipsychotics.
- Dream Potentiation
- Rebound Anxiety: Commonly observed with anxiety-relieving substances like benzodiazepines, rebound anxiety correlates with the duration of substance influence and the total amount consumed within a specific timeframe. This effect can foster cycles of dependence and addiction.
- Dream Potentiation or Dream Suppression
- Residual Sleepiness: Although benzodiazepines aid sleep, their effects may persist into the morning, leaving users “groggy” or “dull” for a few hours.
- Thought Deceleration
- Thought Disorganization
Clonazepam boasts a relatively low toxicity relative to its dosage, but it can become potentially lethal when mixed with other depressants like alcohol or opioids. Thus, it is imperative to adhere to harm-reduction practices when using this drug.
Tolerance and Addiction Potential:
Clonazepam carries a high risk of physical and psychological addiction. Tolerance to its sedative-hypnotic effects typically develops within days of continuous use, with a return to baseline tolerance occurring within 7 to 14 days after cessation. However, in some instances, this recovery period may extend, correlating with the duration and intensity of long-term use.
Abrupt discontinuation of clonazepam after several weeks of consistent dosing may lead to withdrawal or rebound symptoms, necessitating a gradual dose reduction. For guidance on tapering from benzodiazepines in a controlled manner, please refer to this guide.
Withdrawal from benzodiazepines is known to be exceptionally challenging and potentially life-threatening for regular users. Ceasing use without tapering over several weeks elevates the risk of hypertension, seizures, and even death. Substances that lower the seizure threshold, such as tramadol, should be avoided during withdrawal.
Clonazepam establishes cross-tolerance with all benzodiazepines, implying that its consumption reduces the effectiveness of other benzodiazepines.
Benzodiazepine overdose can occur when taken in excessive quantities or conjunction with other depressants. This becomes particularly dangerous when combined with other GABAergic depressants like barbiturates and alcohol, as they act similarly but bind to distinct allosteric sites on the GABAA receptor, enhancing each other’s effects. Benzodiazepines increase the frequency of the chlorine ion pore opening on the GABAA receptor, while barbiturates prolong its duration. Consequently, when both are consumed, the ion pore opens more frequently and remains open longer. Benzodiazepine overdose constitutes a medical emergency that, if not promptly and adequately treated, may lead to coma, permanent brain injury, or death.
Symptoms of benzodiazepine overdose may encompass severe thought deceleration, slurred speech, confusion, delusions, respiratory depression, coma, or even fatality. In a hospital setting, benzodiazepine overdoses can be effectively treated, yielding favorable outcomes. Treatment may sometimes involve flumazenil, a GABAA antagonist, but it is primarily supportive.
Warning: The combination of certain substances can abruptly transform psychoactive compounds from reasonably safe to potentially life-threatening. Below is a list of known dangerous interactions, although it may not encompass all. Independent research (e.g., via Google, DuckDuckGo, PubMed) should always be conducted to ensure the safety of combining two or more substances. Some of these interactions have been sourced from TripSit.
- Depressants (1,4-Butanediol, 2M2B, alcohol, benzodiazepines, barbiturates, GHB/GBL, methaqualone, opioids): This combination amplifies muscle relaxation, amnesia, sedation, and respiratory depression. At higher doses, it can lead to sudden, unexpected loss of consciousness, along with dangerously depressed respiration. There’s also an increased risk of suffocation if nausea or vomiting occurs before loss of consciousness, making it crucial to fall asleep in the recovery position or have assistance from a friend.
- Dissociatives: Combining these substances can unpredictably enhance amnesia, sedation, motor control loss, and delusions. It may lead to sudden consciousness loss and severe respiratory depression. If nausea or vomiting arises before losing consciousness, adopting the recovery position or seeking assistance is advised.
- Stimulants: Stimulants mask the sedative effects of depressants, making it challenging for individuals to gauge their level of intoxication. Once the stimulant effects wane, the depressant effects significantly intensify, resulting in heightened disinhibition, motor control loss, and potentially dangerous black-out states. This combination may also lead to severe dehydration if fluid intake is not closely monitored. If choosing to combine these substances, it’s imperative to limit oneself to a predetermined dosing schedule and monitor intake carefully.
Internationally, clonazepam is classified under the United Nations Convention on Psychotropic Substances as a Schedule IV drug.
Australia: Clonazepam is exclusively available by prescription.
Brazil: Clonazepam is categorized as a “black stripe” medication, accessible solely by prescription.
Canada: Clonazepam is listed as a Schedule IV drug.
Czech Republic: Clonazepam is classified as a Schedule IV (List 7) substance. It can only be obtained with a prescription “without a blue stripe” (§ 1, g), as per Nařízení vlády č. 463/2013 Sb.).
Germany: Clonazepam is regulated under Anlage III BtMG (Narcotics Act, Schedule III) since August 1, 1986. It requires a narcotic prescription form, except for preparations containing up to 2 mg clonazepam per dosage form and solutions containing up to 0.25% and under 250 mg clonazepam per packaging unit.
India: Clonazepam is categorized as Schedule H in India.
Israel: Clonazepam is accessible exclusively by prescription.
New Zealand: Clonazepam is classified as a Schedule 3 controlled drug.
Norway: Clonazepam is available solely by prescription.
Russia: Clonazepam is designated as a Schedule III controlled substance, effective April 2013.
Switzerland: Clonazepam is considered a controlled substance, explicitly mentioned under Verzeichnis B. Medicinal use is permitted.
Turkey: Clonazepam falls under the ‘green prescription’ category, available only with a prescription, and its sale or possession without a prescription is illegal.
United Kingdom: Clonazepam is classified as a Class C drug.
United States: Clonazepam is categorized as a Schedule IV substance.
1. What is Clonazepam?
- Clonazepam is a medication belonging to the benzodiazepine class. It is primarily prescribed to treat anxiety, panic attacks, and certain seizure disorders. It affects the brain’s neurotransmitters, producing calming and soothing effects.
2. How does Clonazepam work?
- Clonazepam enhances the effects of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that helps regulate anxiety and other functions. By increasing GABA activity, Clonazepam reduces the excitability of nerve cells, resulting in a calming effect.
3. What are the common uses of Clonazepam?
- Clonazepam is commonly prescribed for the treatment of:
- Panic disorder
- Generalized anxiety disorder (GAD)
- Social anxiety disorder (SAD)
- Certain seizure disorders, such as Lennox-Gastaut syndrome and absence of seizures
4. How should I take Clonazepam?
- Follow your healthcare provider’s instructions carefully. Typically, Clonazepam is taken orally with or without food. The dosage and frequency will depend on your specific condition and medical history. Do not exceed the prescribed dose.
5. What are the potential side effects of Clonazepam?
- Common side effects may include drowsiness, dizziness, and coordination problems. Less frequently, it can lead to more severe side effects like mood changes, confusion, or allergic reactions. Always consult your healthcare provider if you experience unusual or severe side effects.
6. Is Clonazepam addictive?
- Yes, Clonazepam can be physically and psychologically addictive, mainly if used for an extended period or at higher doses than prescribed. It’s essential to take it as directed by your healthcare provider to minimize the risk of dependence.
7. Can I drink alcohol while taking Clonazepam?
- It is strongly advised to avoid alcohol when taking Clonazepam. Combining the two can lead to increased sedation, impaired coordination, and potentially dangerous respiratory depression.
8. How long does it take for Clonazepam to work?
- Clonazepam typically begins to take effect within 30 to 60 minutes after ingestion. However, it may vary from person to person. It is essential to be patient and not increase the dose if you don’t feel immediate relief.
9. Can I stop taking Clonazepam suddenly?
- No, sudden discontinuation of Clonazepam can lead to withdrawal symptoms, including anxiety, irritability, and even seizures. It is crucial to taper off the medication under the supervision of a healthcare professional when discontinuing it.
10. Is Clonazepam safe during pregnancy and breastfeeding?
Clonazepam may pose risks to a developing fetus and is not recommended during pregnancy unless the potential benefits outweigh the potential risks. It can also pass into breast milk, so consult your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
11. Can Clonazepam interact with other medications?
Yes, Clonazepam can interact with various drugs. Inform your healthcare provider about all your medications, supplements, and herbs to avoid potential interactions. It is important to mention other central nervous system depressants or medications that affect liver enzymes.
12. How should I store Clonazepam?
Store Clonazepam at room temperature, away from moisture, heat, and light. Keep it out of reach of children and pets. Do not share this medication with others, even if they have similar symptoms.
13. Is Clonazepam available over-the-counter (OTC)?
No, Clonazepam is not available over-the-counter. It requires a prescription from a qualified healthcare provider.
14. Can I drive or operate heavy machinery while taking Clonazepam?
Clonazepam can impair coordination and reaction times. It is advisable to avoid activities that require mental alertness, such as driving or operating heavy machinery, until you know how the medication affects you.
15. What should I do if I miss a dose of Clonazepam?
If you miss a dose, take it as soon as you remember. However, if it’s close to the time for your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Do not double the dose to make up for the missed one.
- Patent US3123529 (PDF): This patent document possibly contains crucial information about the risks when combining depressants, although the exact content may vary.
- Cowen, P. J., Green, A. R., Nutt, D. J. (Mar 5, 1981). “Ethyl beta-carboline carboxylate lowers the seizure threshold and antagonizes flurazepam-induced sedation in rats.” Nature. 290 (5801): 54–55: This research study explores the effects of ethyl beta-carboline carboxylate on seizure threshold and its interaction with flurazepam-induced sedation in rats.
- Basit H, Kahwaji CI. Clonazepam. [Updated 2022 Sep 1]. In: StatPearls: This source, updated in September 2022, likely discusses Clonazepam and its relevance to depressants, although specific details can differ.
- Lann, M. A., Molina, D. K. (June 2009). “A fatal case of benzodiazepine withdrawal”. The American Journal of Forensic Medicine and Pathology. 30 (2): 177–179: This study delves into a fatal case related to benzodiazepine withdrawal, highlighting the potential risks of discontinuing depressant use.
- Kahan, M., Mailis-Gagnon, A., Tunks, E. (June 2011). “Canadian guideline for safe and effective use of opioids for chronic non-cancer pain: implications for pain physicians.” Pain Research & Management. 16 (3): 157–158: This Canadian guideline might contain insights into the safe use of opioids for pain management, which can intersect with depressants.
- Haefely, W. (Jun 29 1984). “Benzodiazepine interactions with GABA receptors”. Neuroscience Letters. 47 (3): 201–206: This research paper explores the interactions between benzodiazepines and GABA receptors, shedding light on potential mechanisms underlying depressant effects.
- McLean, M. J., Macdonald, R. L. (February 1988). “Benzodiazepines, but not beta carbolines, limit high-frequency repetitive firing of action potentials of spinal cord neurons in cell culture.” The Journal of Pharmacology and Experimental Therapeutics. 244 (2): 789–795: This study investigates how benzodiazepines impact the firing of action potentials in spinal cord neurons, offering insights into their effects.
- Saïas, T., Gallarda, T. (September 2008). “[Paradoxical aggressive reactions to benzodiazepine use: a review]”. L’Encephale. 34 (4): 330–336: This review discusses paradoxical aggressive reactions linked to benzodiazepine use, highlighting unexpected consequences.
- Paton, C. (December 2002). “Benzodiazepines and disinhibition: a review.” Psychiatric Bulletin. 26 (12): 460–462: This review article likely discusses the potential for disinhibition associated with benzodiazepines, an important consideration when combining depressants.
- Bond, A. J. (Jan 1 1998). “Drug-Induced Behavioural Disinhibition.” CNS Drugs. 9 (1): 41–57: This article might explore how drugs can induce behavioral disinhibition, which is pertinent to discussing depressant interactions.
- Goyal, S. (Mar 14 1970). “Drugs and dreams”. Canadian Medical Association Journal. 102 (5): 524: This source could provide insights into the connection between drugs, including depressants, and dream patterns.
- Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (Mar 24, 2007). “Development of a rational scale to assess the harm of drugs of potential misuse.” The Lancet. 369 (9566): 1047–1053: This article presents a rational scale for assessing the harm of potentially misused drugs, which includes depressants.
- Mandrioli, R., Mercolini, L., Raggi, M. A. “Benzodiazepine Metabolism: An Analytical Perspective”. Current Drug Metabolism. 9 (8): 827–844: This analytical perspective likely explores the metabolism of benzodiazepines, a critical aspect of understanding their effects when combined with other depressants.
- Twyman, R. E., Rogers, C. J., Macdonald, R. L. (March 1989). “Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital.” Annals of Neurology. 25 (3): 213–220: This research article investigates the differential regulation of GABA receptor channels by diazepam and phenobarbital, which are relevant to depressant interactions.
- Hoffman, E. J., Warren, E. W. (September 1993). “Flumazenil: a benzodiazepine antagonist”. Clinical Pharmacy. 12 (9): 641–656; quiz 699–701: This article likely discusses flumazenil, a benzodiazepine antagonist, which can be crucial in managing depressant overdose or interactions.
- “List of Psychotropic Substances under International Control” (PDF). International Narcotics Control Board: This document could provide information about psychotropic substances under international control, including some depressants.
- Anvisa: This source may contain regulations or information about depressants in a specific region, possibly Brazil.
- Various External Links: These links could provide additional information about regulations and substances related to depressants in different countries.
- Misuse of Drugs Act 1975 No 116 (as of Jul 1, 2022), Public Act Schedule 3 Class C controlled drugs – New Zealand Legislation: This Act likely contains information about the classification and regulation of controlled drugs, including depressants, in New Zealand.
- “Постановление Правительства РФ от 04.02.2013 N 78 “О внесении изменений в некоторые акты Правительства Российской Федерации” – КонсультантПлюс: This Russian government resolution may pertain to changes in regulations related to depressants in Russia.
- “Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien” (in German). Bundeskanzlei [Federal Chancellery of Switzerland]: This German document may contain listings and regulations regarding controlled substances, potentially including depressants.
- **YEŞİL REÇETEYE TABİ İLAÇLAR | https://www.titck.gov.tr/storage/Archive/2019/contentFile/01.04.2019%20SKRS%20Ye